Yutian Ma

Jul 11, 2024 | dialnet.unirioja.es | Wenwen Li |Yutian Ma

IdiomacatalàDeutschEnglishespañoleuskarafrançaisgalegoitalianoportuguêsromână

Jul 3, 2024 | onlinelibrary.wiley.com | Yue Zhang |Yutian Ma |Lili Wang |Chunyan Li

Conflict of Interest The authors declare no conflict of interest. Supporting Information Filename Description smll202403629-sup-0001-SuppMat.pdf979.2 KB Supporting Information References 1, , , , Exploration 2021, 1, 20210101. 2, Chem. Soc. Rev. 2010, 39, 901. 3, , , , Chem. Soc. Rev. 2017, 46, 5400. 4, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , et al., Chem. Rev. 2023, 123, 2737. 5, , , , , , , , , , , Adv. Funct. Mater. 2024, 34, 2314165.

Aug 30, 2023 | dx.doi.org | Yutian Ma |Shiyao Li |Xin Lin |Yupeng Chen

Ribonucleic acid (RNA)-based therapies have become an attractive topic in disease intervention, especially with some that have been approved by the FDA such as the mRNA COVID-19 vaccine (Comirnaty, Pfizer-BioNTech, and Spikevax, Moderna) and Patisiran (siRNA-based drug for liver delivery). However, extensive applications are still facing challenges in delivering highly negatively charged RNA to the targeted site.